Variable Summarya (N=12)
Completed 3 month treatment of 3 drugs in study 12 (100%)
Completed 6 month follow-up 11 (92%)
Age at consent date 69 (62, 76)
Sex - Female 9 (75%)
Race - Caucasian 12 (100%)
Change in disease severity prior to enrollment  
Stable 6 (50%)
Slight deterioration 1 (8%)
Worse 5 (42%)
Never smokedb 7 (58%)
History of hemoptysis in last 6 months 2 (17%)
Hemoptysis while on treatment 0 (0%)
BMI (kg/m2) 23.2 (18.6, 23.9)
FEV1 (L) 1.8 (1.3, 2.0)
pp FEV1 (%) 64 (47, 70)
FEV1/FVC (%) 63 (59, 74)
DLCO 14.0 (11.7, 17.2)
pp DLCO (%) 66 (60, 74)
aThe sample median (25th, 75th percentiles) is given for numerical variables, n (%) for categorical variables. bNo patients were current smokers.
Table 1: Baseline patient characteristics.